Table 3.
The PROTACs developed for the undruggable targets in cancers.
| Targets | PROTACS | Disease | Structure | Reference |
|---|---|---|---|---|
| KRAS | YF135 | Non-small cell lung cancer |
|
289 |
| KRAS | KP-14 | Non-small cell lung cancer |
|
290 |
| KRAS | LC-2 | Lung cancer, Pancreatic cancer |
|
41 |
| SHP2 | ZB-S-29 | Monocytic leukemia |
|
291 |
| SHP2 | SHP2-D26 | Esophageal cancer, Monocytic leukemia |
|
292 |
| SHP2 | SP4 | Cervical cancer |
|
293 |
| SHP2 | R1-5C | Monocytic leukemia, Esophageal cancer, Acute myelogenous leukemia, Acute lymphoblastic leukemia |
|
294 |
| BRD4(C-MYC) | ARV-825 | Burkitt's Lymphoma, B cell lymphoma |
|
165 |
| STAT3 | SD-36 | Acute myelogenous leukemia, Anaplastic large cell lymphoma |
|
114 |
| STAT3 | SD-91 | Acute myelogenous leukemia |
|
295 |
| AR-V7 | MTX-23 | Castration-resistant prostate cancer |
|
296 |
| AR-V7 | 6 | Castration-resistant prostate cancer |
|
297 |
| β-catenin | xStAx-VHLL | Rectal cancer |
|
298 |
| p300/CBP | dCBP-1 | Multiple myeloma |
|
299 |
| EP300 | JQAD1 | Neuroblastoma |
|
300 |
| SMARCA2 | A947 | Non-small cell lung cancer |
|
301 |